CN1089265A - 制备咪唑并吡啶的方法 - Google Patents
制备咪唑并吡啶的方法 Download PDFInfo
- Publication number
- CN1089265A CN1089265A CN93109331A CN93109331A CN1089265A CN 1089265 A CN1089265 A CN 1089265A CN 93109331 A CN93109331 A CN 93109331A CN 93109331 A CN93109331 A CN 93109331A CN 1089265 A CN1089265 A CN 1089265A
- Authority
- CN
- China
- Prior art keywords
- chloro
- amino
- biphenyl
- ylmethyl
- cyano group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种制备式I的咪唑并吡啶的新方
法。
该法的特征在于,3,4-二氨基-2-氯吡啶(II)与
式RCO-O-COR′(III)的酸酐反应,得到4-氨基
-2-氯-3-R-CO-氨基吡啶(IV),其中R如上规定,
R1为R或可为另外的脂族或芳族基团,在碱金属醇
化物存在下,在惰性溶剂中,用4′-溴甲基-2-氰基
联苯(V)将(VI)转化成4-氨基-2-氯-3-R-CO-
[N-(2′-氰基-联苯-4-基甲基)氨基]吡啶(VI),(VI)
与强酸反应,生成2-R-4-氯-3-(2′-氰基-联苯
-4-基甲基)-3H-咪唑并[4,5-C]吡啶(VII),作为中
间体。
Description
本发明涉及一种制备式Ⅰ的咪唑并吡啶的新方法
其中R为有1至6个碳原子的烷基,该方法的特征在于,3,4-二氨基-2-氯吡啶(Ⅱ)与式RCO-O-COR′(Ⅲ)的酸酐反应,得到4-氨基-2-氯-3-R-CO-氨基吡啶(Ⅳ),其中R如上规定,R′为R或可为另外的脂族或芳族基团,在碱金属醇化物存在下,在惰性溶剂中,用4′-溴甲基-2-氰基联苯(Ⅴ)将(Ⅳ)转化成4-氨基-2-氯-3-R-CO-[N-(2′-氰基-联苯-4-基甲基)氨基]吡啶(Ⅵ),(Ⅵ)与强酸反应,生成2-R-4-氯-3-(2′-氰基-联苯-4-基甲基)-3H-咪唑并[4,5-C]吡啶(Ⅶ)作为中间体。
式Ⅰ化合物有抑制血管紧张肽Ⅱ的作用,因此可用作药物活性成分,特别是用于降低血压的药物活性成分。它们也是适合用于制备其他药物活性成分的中间体。
基团R最好是直链烷基,优选的是丁基或丙基,要不然就是甲基、乙基、戊基、己基、异丙基、异丁基、仲丁基、叔丁基、1-、2-或3-甲基丁基、1,1-、1,2-或2,2-二甲基丙基、1-、2-或3-、或4-甲基戊基、1-或2-乙基丁基、1,1-、1,2-、1,3-、2,2-、2,3-或3,3-二甲基丁基或1,1,2-或1,2,2-三甲基丙基。
基团R′优选的是R,在这种情况下Ⅲ是单一酸酐。但是,基团R′也可为另外的脂族或芳族基团,在这种情况下Ⅲ是“混合”酸酐。在每种情况下在这里R′最好是至多有10个碳原子的脂族或芳族烃基。例如烷基,特别是支链烷基(如叔丁基)或未取代的或被1至5个低级烷基特别是甲基取代的苯基(如3,5-二甲基苯基或2,4,6-三甲基苯基)。
通常在多磷酸或POCl3存在下,在相当高的温度下,通过与式R-COOH的酸反应实现3,4-二氨基吡啶向2-R-咪唑并[4,5-C]吡啶的转化。例如,如果在多磷酸存在下,在100至180℃下Ⅱ与戊酸反应,得到2-丁基-4,5-二氢-4-氧-1(或3)H-咪唑并[4,5-C]吡啶作为主要产物,同时有氯原子水解。这样就有在与Ⅴ的“烷基化”中生成产物混合物的缺点。
本发明的目的是要避免传统方法的这一缺点,并要找到一种方法,在这一方法中,在任何步骤中与Ⅴ的“烷基化”都选择性地发生在所希望的位置。通过本申请要求的方法达到了这一目的。
事实上,如果Ⅱ与酸酐Ⅲ反应,那么可选择性的得到高产率的Ⅳ。这一反应最好在相当缓和的条件下,在惰性溶剂存在下,在0至100℃下,特别是在10至50℃下进行,使用计算量的Ⅲ进行,换句话说Ⅲ不过量。适合溶剂的例子是醚,如四氢呋喃(THF)或二噁烷。
按照本发明,Ⅳ与Ⅴ的反应(由欧洲专利253310实施例89已知)在惰性溶剂中,优选的是在极性溶剂中(如酰胺(如二甲基甲酰胺)或丙酰胺(如N-甲基吡咯烷酮(NMP)),在碱存在下,优选的是碱金属醇化物存在下(如叔丁醇钾,要不就是甲醇钠或甲醇钾,或乙醇钠或乙醇钾)进行。
该反应最好在约0至50℃,特别是10至20℃下进行,其步骤是首先用醇化物使Ⅳ脱质子,然后滴加Ⅴ的溶液。令人吃惊的是,在这样的条件下,选择性地得到Ⅵ作为主要产物,而通过脱水生成的Ⅶ为副产物。
然后用强酸,优选的是强无机酸(如盐酸或硫酸),最好是补充的惰性溶剂或溶剂混合物(如水/NMP)存在下,通常在0至110℃(优选的是100至110℃)下处理生成的Ⅵ(或Ⅶ或Ⅵ和Ⅶ的混合物)。因此Ⅵ被环化成Ⅶ,而氯原子还通过水解消除。
也可将几个步骤结合起来,以致不用分离中间产物。具体地说,可分别进行Ⅵ与Ⅴ生成Ⅵ或Ⅶ的反应,随后一步消除氯原子;在这种情况下,Ⅵ和Ⅶ不需分离。
所有的温度都以摄氏度给出。
实施例1
(a)将186克戊酸酐滴加到143.5克,3,4-二氨基-2-氯吡啶在1350毫升THF中的溶液中,该混合物在20℃下搅拌16小时。将1升饱和NaHCO3溶液和340毫升饱和Na2CO3溶液加入。过滤混合物,用乙酸乙酯抽提滤液,用Na2SO4干燥抽提物并蒸发得到4-氨基-2-氯-3-戊酰胺基吡啶(Ⅳa),熔点163℃。
(b)在10至15℃下,在搅拌下将36.8克叔丁醇钾在100毫升NMP中的溶液滴加到64.9克Ⅳa在300毫升NMP中的溶液中。进一步搅拌0.5小时后,在10至15℃下滴加85.2克Ⅴ在300毫升NMP中的溶液。进一步搅拌16小时后,用乙酸乙酯和饱和NaCl溶液处理该混合物。粗产物从乙酸乙酯/叔丁基甲基醚中结晶得到40克4-氨基-2-氯-3-N-(2′-氰基-联苯-4-基甲基)戊酰胺基吡啶(Ⅵa),熔点144℃。母液重结晶还可得到13.7克2-丁基-4-氯-3-(2′-氰基联苯-4-基甲基)-3H-咪唑并[4,5-C]吡啶(Ⅶa),熔点133.5℃。
(c)在105℃下将43.1克(Ⅵa)、36.2克Ⅶa、2000毫升15%盐酸和1200毫升NMP的混合物搅拌48小时。冷却混合物,用氢氧化钠溶液将pH值调节到9,用乙酸乙酯抽提混合物,过滤抽提物,用水洗涤,并用Na2SO4干燥,得到64克2-丁基-3-(2′-氰基-联苯-4-基-甲基)-4,5-二氢-4-氧-3H-咪唑并[4,5-C]吡啶(Ⅰa),熔点165℃。
实施例2
在氮气下制备227.7克Ⅳa在1000毫升NMP中的溶液,在5至10℃下,在搅拌下滴加129.1克叔丁醇钾在400毫升NMP中的溶液,继续搅拌1小时,在5至10℃下,在搅拌下滴加299.4克Ⅴ在750毫升NMP中的溶液。在20℃下搅拌5小时后,加入3100毫升18%盐酸,该混合物加热到105℃下40小时。然后将混合物冷却到80℃,并滴加3700毫升16%氢氧化钠溶液。将混合物冷却,过滤出沉淀Ⅰa,用水洗涤并从1∶1乙醇/水中重结晶,得到316克纯的Ⅰa,熔点165℃。
Claims (1)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4225835A DE4225835A1 (de) | 1992-08-05 | 1992-08-05 | Verfahren zur Herstellung von Imidazopyridinen |
DEP4225835.9 | 1992-08-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1089265A true CN1089265A (zh) | 1994-07-13 |
Family
ID=6464864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN93109331A Pending CN1089265A (zh) | 1992-08-05 | 1993-08-05 | 制备咪唑并吡啶的方法 |
Country Status (16)
Country | Link |
---|---|
US (1) | US5321137A (zh) |
EP (1) | EP0582146A3 (zh) |
JP (1) | JPH06157526A (zh) |
KR (1) | KR940003956A (zh) |
CN (1) | CN1089265A (zh) |
AU (1) | AU4434593A (zh) |
CA (1) | CA2101789A1 (zh) |
CZ (1) | CZ150893A3 (zh) |
DE (1) | DE4225835A1 (zh) |
HU (1) | HUT64956A (zh) |
MX (1) | MX9304722A (zh) |
NO (1) | NO932783L (zh) |
PL (1) | PL299917A1 (zh) |
SK (1) | SK77893A3 (zh) |
TW (1) | TW232693B (zh) |
ZA (1) | ZA935657B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2708612B1 (fr) * | 1993-08-05 | 1996-03-01 | Roussel Uclaf | Nouveaux dérivés bicycliques de l'imidazole, leur procédé de préparation, les nouveaux intermédiaires obtenus, leur application à titre de médicaments et les compositions pharmaceutiques les renfermant. |
DE4341453A1 (de) * | 1993-12-06 | 1995-06-08 | Merck Patent Gmbh | Imidazopyridine |
DE4432860A1 (de) * | 1994-09-15 | 1996-03-21 | Merck Patent Gmbh | Imidazopyridine |
KR100707602B1 (ko) | 2005-10-20 | 2007-04-13 | 삼성에스디아이 주식회사 | 유기 전계 발광 표시장치 및 그의 제조방법 |
TWI324493B (en) | 2006-05-19 | 2010-05-01 | Au Optronics Corp | Lectro-luminescence panel, el panel |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5138069A (en) * | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
US4880804A (en) * | 1988-01-07 | 1989-11-14 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking benzimidazoles |
IE64514B1 (en) * | 1989-05-23 | 1995-08-09 | Zeneca Ltd | Azaindenes |
IL94390A (en) * | 1989-05-30 | 1996-03-31 | Merck & Co Inc | The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them |
DE4110019C2 (de) * | 1991-03-27 | 2000-04-13 | Merck Patent Gmbh | Imidazopyridine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen |
-
1992
- 1992-08-05 DE DE4225835A patent/DE4225835A1/de not_active Withdrawn
-
1993
- 1993-07-23 EP EP19930111782 patent/EP0582146A3/de not_active Withdrawn
- 1993-07-23 SK SK778-93A patent/SK77893A3/sk unknown
- 1993-07-26 CZ CZ931508A patent/CZ150893A3/cs unknown
- 1993-07-30 AU AU44345/93A patent/AU4434593A/en not_active Abandoned
- 1993-08-02 JP JP5191243A patent/JPH06157526A/ja active Pending
- 1993-08-02 KR KR1019930014922A patent/KR940003956A/ko not_active Application Discontinuation
- 1993-08-03 CA CA002101789A patent/CA2101789A1/en not_active Abandoned
- 1993-08-03 TW TW082106194A patent/TW232693B/zh active
- 1993-08-03 PL PL93299917A patent/PL299917A1/xx unknown
- 1993-08-04 NO NO932783A patent/NO932783L/no unknown
- 1993-08-04 US US08/102,175 patent/US5321137A/en not_active Expired - Fee Related
- 1993-08-04 MX MX9304722A patent/MX9304722A/es unknown
- 1993-08-04 ZA ZA935657A patent/ZA935657B/xx unknown
- 1993-08-05 CN CN93109331A patent/CN1089265A/zh active Pending
- 1993-08-05 HU HU9302277A patent/HUT64956A/hu unknown
Also Published As
Publication number | Publication date |
---|---|
NO932783D0 (no) | 1993-08-04 |
HUT64956A (en) | 1994-03-28 |
EP0582146A2 (de) | 1994-02-09 |
JPH06157526A (ja) | 1994-06-03 |
HU9302277D0 (en) | 1993-10-28 |
KR940003956A (ko) | 1994-03-14 |
MX9304722A (es) | 1994-02-28 |
CZ150893A3 (en) | 1994-03-16 |
SK77893A3 (en) | 1994-06-08 |
NO932783L (no) | 1994-02-07 |
PL299917A1 (en) | 1994-04-18 |
CA2101789A1 (en) | 1994-02-06 |
TW232693B (zh) | 1994-10-21 |
US5321137A (en) | 1994-06-14 |
ZA935657B (en) | 1994-03-07 |
EP0582146A3 (en) | 1994-06-15 |
DE4225835A1 (de) | 1994-02-10 |
AU4434593A (en) | 1994-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU999972A3 (ru) | Способ получени производных пиридо-(1,2-а) пиримидина или их фармацевтически приемлемых солей,или их оптически активных изомеров | |
CN103694237A (zh) | 一种抗凝血药阿哌沙班的制备方法及关键中间体 | |
EP0133530A2 (de) | 1,6-Naphthyridinon-Derivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel | |
CN1089265A (zh) | 制备咪唑并吡啶的方法 | |
SU481155A3 (ru) | Способ получени -(фурил-метил)морфинанов | |
US4464361A (en) | Adenosine derivatives | |
EP0180834B1 (de) | 4-Alkoxy-pyrido[2,3-d]pyrimidin-Derivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel | |
CS256397B2 (en) | Method of new pyridylmethylthiothieno-(2,3-d)imidazole derivatives production | |
EP0089022A2 (en) | Alkanoylpyridinones useful as cardiotonics and preparation thereof | |
CA1218659A (en) | 1,3-dioxolo¬4,5-g|quinoline compounds | |
US3887570A (en) | Derivatives of pyrazolo(3,4-b)thieno(2,3-d)pyridine-2-carboxylic acids | |
NO781051L (no) | Kinazolinderivater. | |
US4492710A (en) | Substituted pyrrolidinyl-benzoic acid derivatives and a process for their manufacture | |
JPH0568477B2 (zh) | ||
US4355166A (en) | Quinuclidinic ester and derivatives of phenoxycarboxylic acids | |
EP0062068B1 (en) | N-phthalidyl-5-fluorouracil derivatives | |
US4451469A (en) | Selected 6-alkyl-and 4,6-dialkyl-2(1H)-pyridinones as cardiotonics | |
EP0026675B1 (en) | 1-azaxanthone-3-carboxylic acids, their preparation and pharmaceutical compositions containing them | |
US4552967A (en) | Process for the synthesis of intermediates in the preparation of diaminopyridines | |
JP3251713B2 (ja) | N−チエニルアミノメチレン酢酸誘導体の製造方法 | |
CH578535A5 (en) | Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props | |
JPS59216888A (ja) | 5―オキソ―5H―〔1〕ベンゾピラノ〔2,3―b〕ピリジン誘導体,その製造法および治療剤 | |
US3403160A (en) | Di-beta-pyridyl methyl esters of isocinchomeronic acid | |
US2657212A (en) | Diethanolaminopyridines | |
KR100249554B1 (ko) | 6-치환된 스테로이드, 그것의 제조방법 및 그것을 포함하는 제약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |